^
Association details:
| Biomarker: | PTEN mutation + MSI-H/dMMR |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/ dMMR gastrointestinal tumors
Published date:
04/29/2021
Excerpt:
Forty-five patients with MSI-H/dMMR GI tumors, including gastric cancer, colorectal cancer, cholangiocarcinoma, small intestine cancer, pancreatic cancer, and duodenal cancer, receiving PD-1 blockade were analyzed....PTEN mutations, which were mutually exclusive with a low TMB, were significantly associated with a lower ORRs than wild-type PTEN (21.4 vs 54.8%; odds: 4.45, P = 0.045)....Low TMBs and PTEN mutations...negative predictors of PD-1 blockade responses in patients with MSI-H/dMMR GI tumors.
DOI:
10.1158/1078-0432.CCR-21-0401
